

Table 1a - A line listing of UK spontaneous suspected adverse drug reaction reports in association with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and cataract conditions up to and including 02/05/2022.
Data run completed on 04/05/2022.

Case	Drug Ingredient	Drug Name as Classified	Dose (DF - Dosage form) (mg - Milligrams)	Time to Onset (Days)	Route of Administration	Reaction	Reaction Outcome	Patient Medical History
1	Tezacaftor/Ivacaftor	Symkevi	Unknown	108	Oral Use	Vision blurred, Cataract	Recovered/resolved, Unknown	Cystic fibrosis related diabetes, Pancreatic failure
2	Tezacaftor/Ivacaftor/Elexacaftor	Kaftrio	2 DF	181	Oral Use	Cataract	Not recovered/not resolved	Unknown
3	Tezacaftor/Ivacaftor, Ivacaftor	Symkevi, Ivacaftor	1 DF, 150 mg	309	All Oral Use	Lenticular opacities	Not recovered/not resolved	Unknown
4	Tezacaftor/Ivacaftor/Elexacaftor, Ivacaftor	Kaftrio, Kalydeco	Unknown, 150 mg	Unknown	All Oral Use	Cataract	Not recovered/not resolved	Cystic fibrosis
5	Tezacaftor/Ivacaftor/Elexacaftor, Tezacaftor/Ivacaftor	Kaftrio, Kalydeco	All Unknown	Unknown	All Oral Use	Lenticular opacities, Cataract subcapsular	Unknown, Unknown	Cystic fibrosis
6	Ivacaftor	Ivacaftor	150 mg	Unknown	Oral Use	Cataract subcapsular	Unknown	Cystic fibrosis pancreatic, Hepatosplenomegaly, Thrombocytopenia, Liver disorder
7	Tezacaftor/Ivacaftor/Elexacaftor, Ivacaftor	Kaftrio, Kalydeco	All Unknown	Unknown	All Oral Use	Cataract	Unknown	Cystic fibrosis
8	Tezacaftor/Ivacaftor, Ivacaftor	Symkevi, Kalydeco	1 DF, 150 mg	337	All Oral Use	Eye opacity, Cataract	Unknown, Not recovered/not resolved	Cystic fibrosis, Exposure to radiation
9	Tezacaftor/Ivacaftor, Ivacaftor	Symkevi, Kalydeco	Unknown, 75 mg	353	All Oral Use	Cataract	Unknown	Cystic fibrosis

Table 1b - Aggregated patient sex

Patient Sex	Total
Female	6
Male	3
Unknown	0
Total	9

Table 1c - Aggregated patient age

Patient Age Group	Total
03 - 12	2
13 - 17	3
18 - 35	0
36 - 65	2
66+	0
Unknown	2
Total	9